# US 2015/0105418 A1 · Substituted hydroxamic acids and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105418 A1
- Document ID: US20150105418A1
- Status: Published application
- Kind: A1
- Application number: 14/573,615
- Filed: 2014-12-17
- Published: 2015-04-16
- Earliest claimed: 2010-08-26
- Assignees: Millennium Pharmaceuticals, Inc.
- Inventors: Christopher Blackburn; Kenneth M. Gigstad; He Xu
- Web page: https://patentgrep.com/patent/US20150105418A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 215/54: attached in position 3
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides compounds of formula (I): wherein R1a, R1b, R1c, R1d, R2a, R2b, X1, X2, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
one of X1 and X2 is CR1 and the other is N; or both X1 and X2 are N;
one of R2a and R2b is R1, and the other is —C(O)—NH—OH;
R1a is hydrogen, fluoro, C1-4 alkyl, or C1-4 fluoroalkyl;
R1b is hydrogen, fluoro, C1-4 alkyl, or C1-4 fluoroalkyl;
or R1a and R1b are taken together to form a 3 to 6 membered cycloaliphatic;
R1c and R1d are:
I) each occurrence of R1c is independently hydrogen, fluoro, C1-4 alkyl, or C1-4 fluoroalkyl; and each occurrence of R1d is independently hydrogen, fluoro, C1-4 alkyl, or C1-4 fluoroalkyl; or
II) two occurrences of R1c are taken together to form ═O; and each occurrence of R1d is independently hydrogen, fluoro, C1-4 alkyl, or C1-4 fluoroalkyl; or
III) two occurrences of R1d are taken together to form ═O; and each occurrence of R1c is independently hydrogen, fluoro, C1-4 alkyl, or C1-4 fluoroalkyl;
each occurrence of R1 is independently hydrogen, chloro, fluoro, —O—C1-4 alkyl, cyano, hydroxy, C1-4 alkyl, or C1-4 fluoroalkyl;
G is —R3, —V1—R3, —V1-L1-R3, -L2-V1—R3, L2-V2—R3, —V1-L1-V2—R3, or -L1-R3;
L1 is unsubstituted or substituted C1-3 alkylene chain;
L2 is unsubstituted or substituted C2-3 alkylene chain;
V1 is —C(O)—, —C(S)—, —C(O)—N(R4a)—, —C(O)—O—, —S(O)2—, or —SO2—N(R4a)—;
V2 is —N(R4a)—, —N(R4a)—C(O)—, —N(R4a)—SO2—, —SO2—N(R4a)—, —SO2—, —C(O)—, —C(O)—O—, —O—C(O)—, —O—, —S—, —N(R4a)—C(O)—N(R4a)—, —N(R4a)—C(O)—O—, —O—C(O)—N(R4a)—, or —N(R4a)—SO2—N(R4a)—;
R3 is unsubstituted or substituted C1-6 aliphatic, unsubstituted or substituted 3-10-membered cycloaliphatic, unsubstituted or substituted 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, unsubstituted or substituted 6-10-membered aryl, or unsubstituted or substituted 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and
each occurrence of R4a is independently hydrogen, or unsubstituted or substituted C1-4 aliphatic.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
R2a is C(O)—NH—OH;
R2b is R1; and
X1 is CR1 and X2 is N.

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
G is —R3, —V1—R3, —V1-L1-R3, or -L1-R3; and
V1 is —C(O)—, —C(O)—N(R4a)—, or —S(O)2—.

### Claim 4 (depends on 1)

The compound of claim 1, wherein:
each occurrence of R1 is independently hydrogen, chloro, fluoro, cyano, hydroxy, methoxy, ethoxy, trifluoromethyl, methyl, or ethyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein:
R1a is hydrogen, fluoro, or methyl;
R1b is hydrogen, fluoro, or methyl;
each occurrence of R1c is independently hydrogen, fluoro, or methyl; and
each occurrence of R1d is independently hydrogen, fluoro, or methyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein:
each substitutable carbon chain atom in R3 is unsubstituted or substituted with 1-2 occurrences of —R5dd;
each substitutable saturated ring carbon atom in R3 is unsubstituted or substituted with ═O, ═C(R5)2, or —R5aa;
each substitutable unsaturated ring carbon atom in R3 is unsubstituted or is substituted with —R5a;
each substitutable ring nitrogen atom in R3 is unsubstituted or substituted with —R9b;
each R5a is independently halogen, —NO2, —CN, —C(R5)═C(R5)2, —C≡C—R5, —OR5, —SR6, —S(O)R6, —SO2R6, —SO2N(R4)2, —N(R4)2, —NR4C(O)R5, —NR4C(O)N(R4)2, —NR4CO2R6, —OC(O)N(R4)2, —C(O)R6, —C(O)N(R4)2, —N(R4)SO2R6, —N(R4)SO2N(R4)2, unsubstituted or substituted C1-6 aliphatic, unsubstituted or substituted 3-10-membered cycloaliphatic, unsubstituted or substituted 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, unsubstituted or substituted 6-10-membered aryl, or unsubstituted or substituted 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or two adjacent R5a, taken together with the intervening ring atoms, form an unsubstituted or substituted fused 5-10 membered aromatic ring or an unsubstituted or substituted 4-10 membered non-aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each occurrence of R5aa is independently chloro, fluoro, hydroxy, unsubstituted or substituted C1-6 aliphatic, —O(C1-6 alkyl), —C1-6 fluoroalkyl, —O—C1-6 fluoroalkyl, cyano, —N(R4)2, —C(O)(C1-6 alkyl), —CO2H, —C(O)NH2, —C(O)NH(C1-6 alkyl), —C(O)N(C1-6 alkyl)2, —NHC(O)C1-6 alkyl, —NHC(O)OC1-6 alkyl, —NHC(O)NHC1-6 alkyl, or —NHS(O)2C1-6 alkyl;
each occurrence of R5dd is independently fluoro, hydroxy, —O(C1-6 alkyl), cyano, —N(R4)2, —C(O)(C1-6 alkyl), —CO2H, —C(O)NH2, —C(O)NH(C1-6 alkyl), —C(O)N(C1-6 alkyl)2, —NHC(O)C1-6 alkyl, —NHC(O)OC1-6 alkyl, —NHC(O)NHC1-6 alkyl, or —NHS(O)2C1-6 alkyl;
each R4 is independently hydrogen, unsubstituted or substituted C1-6 aliphatic, unsubstituted or substituted 3-10-membered cycloaliphatic, unsubstituted or substituted 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, unsubstituted or substituted 6-10-membered aryl, or unsubstituted or substituted 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or two R4 on the same nitrogen atom, taken together with the nitrogen atom, form an unsubstituted or substituted 5- to 6-membered heteroaryl or an unsubstituted or substituted 4- to 8-membered heterocyclyl having, in addition to the nitrogen atom, 0-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur;
each R5 is independently hydrogen, unsubstituted or substituted C1-6 aliphatic, unsubstituted or substituted 3-10-membered cycloaliphatic, unsubstituted or substituted 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, unsubstituted or substituted 6-10-membered aryl, or unsubstituted or substituted 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
each R6 is independently unsubstituted or substituted C1-6 aliphatic, unsubstituted or substituted 3-10-membered cycloaliphatic, unsubstituted or substituted 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, unsubstituted or substituted 6-10-membered aryl, or unsubstituted or substituted 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each R9b is independently —C(O)R6, —C(O)N(R4)2, —CO2R6, —SO2R6, —SO2N(R4)2, unsubstituted C3-10 cycloaliphatic, C3-10 cycloaliphatic substituted with 1-2 independent occurrences of R7 or R8, unsubstituted C1-6 aliphatic, or C1-6 aliphatic substituted with 1-2 independent occurrences of R7 or R8;
each R7 is independently unsubstituted or substituted 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, unsubstituted or substituted 6-10-membered aryl, or unsubstituted or substituted 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and
each R8 is independently chloro, fluoro, —OH, —O(C1-6 alkyl), —CN, —N(R4)2, —C(O)(C1-6 alkyl), —CO2H, —CO2(C1-6 alkyl), —C(O)NH2, —C(O)NH(C1-6 alkyl), or —C(O)N(C1-6 alkyl)2.

### Claim 7 (depends on 6)

The compound of claim 6, wherein:
each substitutable saturated ring carbon atom in R3 is unsubstituted or substituted with —R5aa;
the total number of R5a and R5aa substituents is p;
p is 1-4;
each R5a is independently halogen, cyano, nitro, hydroxy, unsubstituted C1-6 aliphatic, C1-6 aliphatic substituted with 1-2 independent occurrences of R7 or R8, unsubstituted O—C1-6 alkyl, —O—C1-6 alkyl substituted with 1-2 independent occurrences of R7 or R8, C1-6 fluoroalkyl, —O—C1-6 fluoroalkyl, —NHC(O)R6, —C(O)NH(R4), —NHC(O)O—C1-6 alkyl, —NHC(O)NHC1-6 alkyl, —NHS(O)2C1-6 alkyl, —NHC1-6 alkyl, —N(C1-6 alkyl)2, 3-10-membered cycloaliphatic substituted with 0-2 occurrences of —R7a, 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with 0-2 occurrences of R7a, 6-10-membered aryl substituted with 0-2 occurrences of —R7a, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with 0-2 occurrences of —R7a, and
each occurrence of R7a is independently chloro, fluoro, C1-6 aliphatic, C1-6 fluoroalkyl, —O—C1-6 alkyl, —O—C1-6 fluoroalkyl, cyano, hydroxy, —CO2H, —NHC(O)C1-6 alkyl, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C(O)NHC1-6 alkyl, —C(O)N(C1-6 alkyl)2, —NHC(O)NHC1-6 alkyl, —NHC(O)N(C1-6 alkyl)2, or —NHS(O)2C1-6 alkyl.

### Claim 8 (depends on 6)

The compound of claim 6, represented by formula (II-a-i):

### Claim 9 (depends on 8)

The compound of claim 8, wherein:
G is —R3, —V1—R3, —V1-L1-R3, or -L1-R3; and
V1 is —C(O)—, —C(O)—N(R4a)—, or —S(O)2—.

### Claim 10 (depends on 9)

The compound of claim 9, wherein:
each occurrence of R1 is independently hydrogen, chloro, fluoro, cyano, hydroxy, methoxy, ethoxy, trifluoromethyl, methyl, or ethyl.

### Claim 11 (depends on 9)

The compound of claim 9, wherein:
R1a is hydrogen, fluoro, or methyl;
R1b is hydrogen, fluoro, or methyl;
each occurrence of R1c is independently hydrogen, fluoro, or methyl; and
each occurrence of R1d is independently hydrogen, fluoro, or methyl.

### Claim 12 (depends on 9)

The compound of claim 9, wherein:
each substitutable saturated ring carbon atom in R3 is unsubstituted or substituted with —R5aa;
the total number of R5a and R5aa substituents is p;
p is 1-4;
each R5a is independently halogen, cyano, nitro, hydroxy, unsubstituted C1-6 aliphatic, C1-6 aliphatic substituted with 1-2 independent occurrences of R7 or R8, unsubstituted —O—C1-6 alkyl, —O—C1-6 alkyl substituted with 1-2 independent occurrences of R7 or R8, C1-6 fluoroalkyl, —O—C1-6 fluoroalkyl, —NHC(O)R6, —C(O)NH(R4), —NHC(O)O—C1-6 alkyl, —NHC(O)NHC1-6 alkyl, —NHS(O)2C1-6 alkyl, —NHC1-6 alkyl, —N(C1-6alkyl)2, 3-10-membered cycloaliphatic substituted with 0-2 occurrences of R7a, 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with 0-2 occurrences of R7a, 6-10-membered aryl substituted with 0-2 occurrences of R7a, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with 0-2 occurrences of —R7a, and
each occurrence of R7a is independently chloro, fluoro, C1-6 aliphatic, C1-6 fluoroalkyl, —O—C1-6 alkyl, —O—C1-6 fluoroalkyl, cyano, hydroxy, —CO2H, —NHC(O)C1-6 alkyl, —NHC1-6 alkyl, —N(C1-6alkyl)2, —C(O)NHC1-6 alkyl, —C(O)N(C1-6 alkyl)2, —NHC(O)NHC1-6 alkyl, —NHC(O)N(C1-6alkyl)2, or —NHS(O)2C1-6 alkyl.

### Claim 13 (depends on 12)

The compound of claim 12, wherein:
R1a is hydrogen;
R1b is hydrogen;
each occurrence of R1c is hydrogen;
each occurrence of R1d is hydrogen; and
each occurrence of R1 is hydrogen.

### Claim 14 (depends on 6)

The compound of claim 6, represented by formula (II-a-ii):

### Claim 15 (depends on 14)

The compound of claim 14, wherein:
G is —R3, —V1—R3, —V1-L1-R3, or -L1-R3; and
V1 is —C(O)—, —C(O)—N(R4a)—, or —S(O)2—.

### Claim 16 (depends on 15)

The compound of claim 15, wherein:
each occurrence of R1 is independently hydrogen, chloro, fluoro, cyano, hydroxy, methoxy, ethoxy, trifluoromethyl, methyl, or ethyl.

### Claim 17 (depends on 15)

The compound of claim 15, wherein:
R1a is hydrogen, fluoro, or methyl;
R1b is hydrogen, fluoro, or methyl;
each occurrence of R1c is independently hydrogen, fluoro, or methyl; and
each occurrence of R1d is independently hydrogen, fluoro, or methyl.

### Claim 18 (depends on 15)

The compound of claim 15, wherein:
each substitutable saturated ring carbon atom in R3 is unsubstituted or substituted with —R5aa;
the total number of R5a and R5aa substituents is p;
p is 1-4;
each R5a is independently halogen, cyano, nitro, hydroxy, unsubstituted C1-6 aliphatic, C1-6 aliphatic substituted with 1-2 independent occurrences of R7 or R8, unsubstituted O—C1-6 alkyl, —O—C1-6 alkyl substituted with 1-2 independent occurrences of R7 or R8, C1-6 fluoroalkyl, —O—C1-6 fluoroalkyl, —NHC(O)R6, —C(O)NH(R4), —NHC(O)O—C1-6 alkyl, —NHC(O)NHC1-6 alkyl, —NHS(O)2C1-6 alkyl, —NHC1-6 alkyl, —N(C1-6alkyl)2, 3-10-membered cycloaliphatic substituted with 0-2 occurrences of R7a, 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with 0-2 occurrences of R7a, 6-10-membered aryl substituted with 0-2 occurrences of —R7a, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with 0-2 occurrences of —R7a, and
each occurrence of R7a is independently chloro, fluoro, C1-6 aliphatic, C1-6 fluoroalkyl, —O—C1-6 alkyl, —O—C1-6 fluoroalkyl, cyano, hydroxy, —CO2H, —NHC(O)C1-6 alkyl, —NHC1-6 alkyl, —N(C1-6alkyl)2, —C(O)NHC1-6 alkyl, —C(O)N(C1-6alkyl)2, —NHC(O)NHC1-6alkyl, —NHC(O)N(C1-6alkyl)2, or —NHS(O)2C1-6 alkyl.

### Claim 19 (depends on 18)

The compound of claim 18, wherein:
R1a is hydrogen;
R1b is hydrogen;
each occurrence of R1c is hydrogen;
each occurrence of R1d is hydrogen; and
each occurrence of R1 is hydrogen.

### Claim 20 (depends on 6)

The compound of claim 6, represented by formula (II-b-i):

### Claim 21 (depends on 20)

The compound of claim 20, wherein:
G is —R3, —V1—R3, —V1-L1-R3, or -L1-R3; and
V1 is —C(O)—, —C(O)—N(R4a)—, or —S(O)2—.

### Claim 22 (depends on 21)

The compound of claim 21, wherein:
each occurrence of R1 is independently hydrogen, chloro, fluoro, cyano, hydroxy, methoxy, ethoxy, trifluoromethyl, methyl, or ethyl.

### Claim 23 (depends on 21)

The compound of claim 21, wherein:
R1a is hydrogen, fluoro, or methyl;
R1b is hydrogen, fluoro, or methyl;
each occurrence of R1c is independently hydrogen, fluoro, or methyl; and
each occurrence of R1d is independently hydrogen, fluoro, or methyl.

### Claim 24 (depends on 21)

The compound of claim 21, wherein:
each substitutable saturated ring carbon atom in R3 is unsubstituted or substituted with —R5aa;
the total number of R5a and R5aa substituents is p;
p is 1-4;
each R5a is independently halogen, cyano, nitro, hydroxy, unsubstituted C1-6 aliphatic, C1-6 aliphatic substituted with 1-2 independent occurrences of R7 or R8, unsubstituted —O—C1-6 alkyl, —O—C1-6 alkyl substituted with 1-2 independent occurrences of R7 or R8, C1-6 fluoroalkyl, —O—C1-6 fluoroalkyl, —NHC(O)R6, —C(O)NH(R4), —NHC(O)O—C1-6 alkyl, —NHC(O)NHC1-6 alkyl, —NHS(O)2C1-6 alkyl, —NHC1-6 alkyl, —N(C1-6alkyl)2, 3-10-membered cycloaliphatic substituted with 0-2 occurrences of R7a, 4-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with 0-2 occurrences of —R7a, 6-10-membered aryl substituted with 0-2 occurrences of —R7a, or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur substituted with 0-2 occurrences of —R7a, and
each occurrence of R7a is independently chloro, fluoro, C1-6 aliphatic, C1-6 fluoroalkyl, —O—C1-6 alkyl, —O—C1-6 fluoroalkyl, cyano, hydroxy, —CO2H, —NHC(O)C1-6 alkyl, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C(O)NHC1-6 alkyl, —C(O)N(C1-6alkyl)2, —NHC(O)NHC1-6 alkyl, —NHC(O)N(C1-6alkyl)2, or —NHS(O)2C1-6 alkyl.

### Claim 25 (depends on 24)

The compound of claim 24, wherein:
R1a is hydrogen;
R1b is hydrogen;
each occurrence of R1c is hydrogen;
each occurrence of R1d is hydrogen; and
each occurrence of R1 is hydrogen.

### Claim 26 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 1)

A method of treating a proliferative disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 28 (depends on 27)

The method of claim 27, wherein the proliferative disorder is breast cancer, lung cancer, ovarian cancer, multiple myeloma, acute myelogenous leukemia, or acute lymphoblastic leukemia.

### Claim 29 (depends on 1)

A method for inhibiting HDAC6 activity in a patient comprising administering a pharmaceutical composition comprising an amount of a compound of claim 1 effective to inhibit HDAC6 activity in the patient.
